Research Subaward Agreement University of California (DSB.AD003.072)

Area tematica

Scienze biomediche

Area progettuale

Struttura responsabile del progetto di ricerca

Istituto di fisiologia clinica (IFC)

Responsabile di progetto

GIORGIO IERVASI
Telefono: 0503152016
E-mail: iervasi@ifc.cnr.it

Abstract

Evaluate changes in beta cell function and insulin sensitivity via modeling from MMTT
(conducted in collaboration with E. Ferrannini, Pisa, Italy):
We will use the existing glucose and C-peptide data from MMTTs to assess changes from
baseline in the drug treated group and placebo subjects (in a manner similar to that described
previously in assessing subjects at risk for T1DM (33). We will also obtain insulin assays from
the archived MMTT samples, so as to evaluate changes in insulin sensitivity (an additional
potential mechanism of imatinib action (11)). These studies will enable us to determine what
changes in the MMTT response are due to changes in beta cell function versus insulin sensitivity,
and may provide further insights into responder vs non-responder assessments in the drug
treated group. Imatinib has also been shown to increase adiponectin levels (10), which correlates
with an improvement in insulin sensitivity. We will measure this factor at baseline, 3, 6, and 12
months in placebo and drug treated subjects, and see how these changes correlate with
responder status.

Obiettivi

Evaluate changes in beta cell function and insulin sensitivity via modeling from MMTT
(conducted in collaboration with E. Ferrannini, Pisa, Italy):
We will use the existing glucose and C-peptide data from MMTTs to assess changes from
baseline in the drug treated group and placebo subjects (in a manner similar to that described
previously in assessing subjects at risk for T1DM (33). We will also obtain insulin assays from
the archived MMTT samples, so as to evaluate changes in insulin sensitivity (an additional
potential mechanism of imatinib action (11)). These studies will enable us to determine what
changes in the MMTT response are due to changes in beta cell function versus insulin sensitivity,
and may provide further insights into responder vs non-responder assessments in the drug
treated group. Imatinib has also been shown to increase adiponectin levels (10), which correlates
with an improvement in insulin sensitivity. We will measure this factor at baseline, 3, 6, and 12
months in placebo and drug treated subjects, and see how these changes correlate with
responder status.

Data inizio attività

15/02/2018

Parole chiave

Safety & Efficacy of Imatinib for Preserving Betacell Function in NewOnset T1D

Ultimo aggiornamento: 06/06/2025